(Q38257126)

1 September 2017

1 reference

title

Translational research in oncology--10 years of progress and future prospects (English)

1 reference

1 September 2017

James H Doroshow

1

1 reference

1 September 2017

Shivaani Kummar

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

7 October 2014

1 reference

Nature Reviews Clinical Oncology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

11

1 reference

1 September 2017

649-662

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2014.158

1 September 2017

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Perspectives on the development of imatinib and the future of cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Mutational landscape and significance across 12 major cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

What we have learned about pancreatic cancer from mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Patient-derived tumor xenografts: transforming clinical samples into mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Lessons from the cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Contributions of human tumor xenografts to anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Maximizing mouse cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The promise of patient-derived xenografts: the best laid plans of mice and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Organoid cultures for the analysis of cancer phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Cancer and inflammation: an old intuition with rapidly evolving new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Inflammation and colorectal cancer: colitis-associated neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecular mechanisms underlying chronic inflammation-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Role of aspirin in cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Tumor suppressors and cell metabolism: a recipe for cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Metabolic targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Exploiting tumor metabolism: challenges for clinical translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Influence of metabolism on epigenetics and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Finishing the euchromatic sequence of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Discovery and saturation analysis of cancer genes across 21 tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Current status of genome-wide association studies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

GWAS meets TCGA to illuminate mechanisms of cancer predisposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

A call to standardize preanalytic data elements for biospecimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

National Cancer Institute Biospecimen Evidence-Based Practices: a novel approach to pre-analytical standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Stability of phosphoprotein as a biological marker of tumor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Interplay between the cancer genome and epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Tumour heterogeneity and cancer cell plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Intratumor heterogeneity: seeing the wood for the trees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecular analysis of circulating tumour cells-biology and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Drug development in oncology: classical cytotoxics and molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecularly targeted cancer therapy: some lessons from the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Compressing drug development timelines in oncology using phase '0' trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Personalized oncology through integrative high-throughput sequencing: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Pharmacodynamic biomarkers for molecular cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Pharmacodynamic biomarkers: falling short of the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Appraising iniparib, the PARP inhibitor that never was--what must we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Cancer biomarkers: selecting the right drug for the right patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Long-term impact of the 70-gene signature on breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecular aspects of cancer cell resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Safety and feasibility of targeted agent combinations in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Exploiting the curative potential of adoptive T-cell therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Design and development of therapies using chimeric antigen receptor-expressing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecular pathways: interleukin-15 signaling in health and in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Understanding and learning from the success of prophylactic human papillomavirus vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Prognostic implications of HPV in oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Prostate cancer vaccines in combination with additional treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

CAR T cells: driving the road from the laboratory to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Review of functional/anatomical imaging in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

PET/MRI radiotracer beyond ¹⁸F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Patient-derived xenograft models in gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Overcoming resistance to targeted anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Proteogenomic characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Global genomic data-sharing effort kicks off

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

31 March 2020

Pharmacogenomics at work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Molecular analysis for therapy choice: NCI MATCH

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

From cancer genomics to precision oncology--tissue's still an issue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Evolution of Translational Omics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Reading between the lines; understanding drug response in the post genomic era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Papillomavirus-like particle vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.158

Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25286976

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.158

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference